KR101839137B1 - 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 - Google Patents

히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR101839137B1
KR101839137B1 KR1020160131245A KR20160131245A KR101839137B1 KR 101839137 B1 KR101839137 B1 KR 101839137B1 KR 1020160131245 A KR1020160131245 A KR 1020160131245A KR 20160131245 A KR20160131245 A KR 20160131245A KR 101839137 B1 KR101839137 B1 KR 101839137B1
Authority
KR
South Korea
Prior art keywords
amine
oxadiazol
pyrimidin
difluoromethyl
cyclobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020160131245A
Other languages
English (en)
Korean (ko)
Other versions
KR20170043091A (ko
Inventor
김윤태
이창식
오정택
송혜승
최진
이재영
Original Assignee
주식회사 종근당
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 종근당 filed Critical 주식회사 종근당
Publication of KR20170043091A publication Critical patent/KR20170043091A/ko
Application granted granted Critical
Publication of KR101839137B1 publication Critical patent/KR101839137B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020160131245A 2015-10-12 2016-10-11 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물 Active KR101839137B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150142014 2015-10-12
KR1020150142014 2015-10-12

Publications (2)

Publication Number Publication Date
KR20170043091A KR20170043091A (ko) 2017-04-20
KR101839137B1 true KR101839137B1 (ko) 2018-03-26

Family

ID=58517488

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160131245A Active KR101839137B1 (ko) 2015-10-12 2016-10-11 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물

Country Status (21)

Country Link
US (1) US10494355B2 (https=)
EP (1) EP3362445B1 (https=)
JP (1) JP6697074B2 (https=)
KR (1) KR101839137B1 (https=)
CN (1) CN108699048B (https=)
AU (1) AU2016338118B2 (https=)
CA (1) CA3001666C (https=)
DK (1) DK3362445T3 (https=)
ES (1) ES2940413T3 (https=)
FI (1) FI3362445T3 (https=)
HR (1) HRP20230201T1 (https=)
HU (1) HUE061967T2 (https=)
MX (1) MX384527B (https=)
MY (1) MY196174A (https=)
NZ (1) NZ740809A (https=)
PH (1) PH12018500773A1 (https=)
PL (1) PL3362445T3 (https=)
PT (1) PT3362445T (https=)
RU (1) RU2695133C1 (https=)
TW (1) TWI694073B (https=)
WO (1) WO2017065473A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
ES2774510T3 (es) 2015-07-27 2020-07-21 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
RU2709207C2 (ru) 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их
HRP20230201T1 (hr) 2015-10-12 2023-03-31 Chong Kun Dang Pharmaceutical Corp. Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
PY19106549A (es) * 2018-12-21 2021-07-13 Bayer Ag 1,3,4-oxadiazoles y derivados de éstos como nuevos agentes fungicidas
EP3919055A4 (en) * 2019-01-30 2022-11-09 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
CN111848423B (zh) * 2019-04-30 2022-10-14 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
AU2020284606B2 (en) 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
MX2022003490A (es) 2019-09-27 2022-04-25 Takeda Pharmaceuticals Co Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6).
AU2020407664A1 (en) * 2019-12-20 2022-08-18 Tenaya Therapeutics, Inc. Fluoroalkyl-oxadiazoles and uses thereof
WO2021133957A1 (en) * 2019-12-27 2021-07-01 Onkure, Inc. Benzimidazole compounds as hdac6 inhibitors
UY39276A (es) 2020-06-19 2022-01-31 Bayer Ag Uso de compuestos de 1,3,4–oxadiazol–2–ilpirimidina para controlar microorganismos fitopatógenos, métodos de uso y composiciones.
UY39275A (es) 2020-06-19 2022-01-31 Bayer Ag 1,3,4-oxadiazol pirimidinas como fungicidas, procesos e intermediarios para su preparación, métodos de uso y usos de los mismos
BR112022025692A2 (pt) 2020-06-19 2023-02-28 Bayer Ag 1,3,4-oxadiazóis e seus derivados como fungicidas
BR112022025710A2 (pt) 2020-06-19 2023-03-07 Bayer Ag 1,3,4-oxadiazol pirimidinas e 1,3,4-oxadiazol piridinas como fungicidas
WO2021255093A1 (en) 2020-06-19 2021-12-23 Bayer Aktiengesellschaft Active compound combination
MX2023001086A (es) 2020-08-07 2023-03-23 Italfarmaco Spa Nuevos inhibidores selectivos de histona desacetilasa 6 (hdac6) basados en oxadiazol.
EP4308097A4 (en) * 2021-03-15 2025-08-20 Univ Michigan Regents NON-HYDROXAMATE HDAC6 INHIBITORS AND METHODS OF USE THEREOF
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
US11919879B2 (en) 2021-06-16 2024-03-05 Celgene Corporation Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases
CN115572244B (zh) * 2021-06-21 2024-04-30 复旦大学 2’-芳基查尔酮类化合物及其制备方法和在制药中的用途
US20250263405A1 (en) * 2021-11-04 2025-08-21 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof
IL316201A (en) * 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
CA3262628A1 (en) * 2022-08-08 2024-02-15 Italfarmaco S.P.A. HYDRAZIDES DIFLOORO- AND TRIFLUORO-ACETYLE USED AS SELECTIVE HDAC6 INHIBITORS
CN115286615A (zh) * 2022-09-01 2022-11-04 深圳市真味生物科技有限公司 一种消旋尼古丁的制备方法
CN117986146A (zh) * 2023-12-22 2024-05-07 河南优凯制药有限公司 一种枸橼酸喷托维林杂质的制备方法及其检测方法
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1
WO2025250930A1 (en) * 2024-05-31 2025-12-04 Baerenkraft Therapeutics, Llc. Hdac6 inhibitors and method of their use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2008156726A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104744446A (zh) 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871753A (en) 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
KR100265385B1 (ko) 1998-02-27 2000-11-01 윤여표 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003028729A2 (en) 2001-10-03 2003-04-10 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
EP1910385B1 (en) 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
WO2007143822A1 (en) 2006-06-14 2007-12-21 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
MX2009006202A (es) 2006-12-11 2009-06-22 Genentech Inc Composiciones y metodos para el tratamiento de neoplasma.
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (ko) 2007-08-28 2009-06-19 전병태 소화기계 질환개선 및 예방용 식품 조성물
BRPI0817897A2 (pt) 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
EP2207811B1 (en) 2007-11-02 2017-01-04 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
EP2421528A4 (en) 2009-04-20 2012-10-17 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
JP2011008205A (ja) 2009-05-27 2011-01-13 Fujifilm Corp 二軸性光学異方性膜を作製するための組成物
CN103221047B (zh) 2010-01-13 2014-12-17 坦颇罗制药股份有限公司 化合物和方法
JP2013517281A (ja) 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
CN103108867A (zh) 2010-02-25 2013-05-15 皮拉马尔企业有限公司 噁二唑化合物及其制备和用途
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012076989A1 (en) 2010-12-09 2012-06-14 Wockhardt Limited Ketolide compounds
KR101262870B1 (ko) 2011-01-28 2013-05-09 환인제약 주식회사 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물
CN103764635B (zh) 2011-07-08 2016-01-20 诺华股份有限公司 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
US9512083B2 (en) 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013066839A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP6272773B2 (ja) 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
SI3041828T1 (sl) 2013-09-06 2018-10-30 Aurigene Discovery Technologies Limited 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji
ES2704704T3 (es) 2013-12-12 2019-03-19 Chong Kun Dang Pharmaceutical Corp Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden
WO2016082930A1 (en) 2014-11-24 2016-06-02 Grünenthal GmbH Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii
CN106349451B (zh) 2015-07-14 2020-11-13 罗门哈斯公司 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法
FI3328843T3 (fi) 2015-07-27 2023-01-31 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
ES2774510T3 (es) 2015-07-27 2020-07-21 Chong Kun Dang Pharmaceutical Corp Derivados de 1,3,4-oxadiazol sulfamida como inhibidores de histona desacetilasa 6 y composición farmacéutica que comprende los mismos
RU2709207C2 (ru) 2015-08-04 2019-12-17 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-оксадиазольные производные соединения в качестве ингибитора гистондеацетилазы 6 и фармацевтическая композиция, содержащая их
HRP20230201T1 (hr) 2015-10-12 2023-03-31 Chong Kun Dang Pharmaceutical Corp. Oksadiazol aminski spojevi derivati kao inhibitor histonske deacetilaze 6 i farmaceutska kompozicija koja sadrži iste

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032445A1 (ja) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2008156726A1 (en) 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2011133888A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyrimidines, compositions thereof, and methods for their use
US20120027874A1 (en) 2010-05-12 2012-02-02 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104744446A (zh) 2013-12-30 2015-07-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg Med Chem Lett., 2011. Vol.21., pp 5735-5738

Also Published As

Publication number Publication date
PL3362445T3 (pl) 2023-08-07
RU2695133C1 (ru) 2019-07-22
US20180273495A1 (en) 2018-09-27
BR112018007289A2 (pt) 2018-10-23
EP3362445A1 (en) 2018-08-22
AU2016338118A1 (en) 2018-04-12
US10494355B2 (en) 2019-12-03
ES2940413T3 (es) 2023-05-08
AU2016338118B2 (en) 2019-03-14
FI3362445T3 (fi) 2023-03-21
TWI694073B (zh) 2020-05-21
TW201716397A (zh) 2017-05-16
EP3362445A4 (en) 2019-05-22
MX384527B (es) 2025-03-14
WO2017065473A1 (en) 2017-04-20
CA3001666A1 (en) 2017-04-20
EP3362445B1 (en) 2023-01-25
CA3001666C (en) 2021-03-30
MX2018004447A (es) 2018-08-01
KR20170043091A (ko) 2017-04-20
CN108699048B (zh) 2021-12-28
HUE061967T2 (hu) 2023-09-28
JP2018530571A (ja) 2018-10-18
NZ740809A (en) 2019-04-26
PH12018500773B1 (en) 2018-10-29
JP6697074B2 (ja) 2020-05-20
PH12018500773A1 (en) 2018-10-29
CN108699048A (zh) 2018-10-23
HRP20230201T1 (hr) 2023-03-31
DK3362445T3 (da) 2023-02-27
MY196174A (en) 2023-03-20
PT3362445T (pt) 2023-03-20

Similar Documents

Publication Publication Date Title
KR101839137B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 옥사다이아졸 아민 유도체 화합물 및 이를 포함하는 약제학적 조성물
JP6560436B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールスルホンアミド誘導体化合物及びこれを含有する薬剤学的組成物
CN101415683B (zh) 新化合物
AU2013354189B2 (en) Cyclopropylamine derivatives useful as inhibitors of histone demethylases KDM1A
RU2660897C2 (ru) Новые соединения в качестве ингибиторов гистондеацетилазы 6 и содержащие их фармацевтические композиции
CN108289886B (zh) 离子通道抑制化合物、药物制剂和用途
CA3217565A1 (en) Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
JP2022503942A (ja) イソインドリン化合物、その調製方法、医薬組成物および使用
TW200924779A (en) Organic compounds
JP2018523663A (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
AU2013354189A1 (en) Cyclopropylamine derivatives useful as inhibitors of histone demethylases KDM1A
EP3828174A1 (en) Pyridazinone derivative
CN115210233B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
TWI794294B (zh) 吡唑衍生化合物及其用途
JP2023539362A (ja) ヒストン脱アセチル化酵素６阻害剤としての新規な構造の化合物およびこれを含む薬剤学的組成物
JPWO2008059854A1 (ja) ピペリジン誘導体またはその塩
JP2011507850A (ja) Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
TW202239756A (zh) 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑硫羰基化合物及包含該等化合物之醫藥組合物
KR102537616B1 (ko) 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
WO2011146300A1 (en) Novel prolylcarboxypeptidase inhibitors
JP2024519091A (ja) 炎症性疾患またはがんを処置するためのオキソインドリン化合物
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
TW202502756A (zh) 作為ｉｌ１７的調節劑的新穎化合物
JP2009523747A (ja) α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20201228

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20211227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20221214

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9